Crenigacestat

Drug Profile

Crenigacestat

Alternative Names: LY-3039478

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 08 Sep 2017 Updated safety, efficacy and pharmacodynamics data from a phase I trial in Solid tumours and lymphoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Preclinical trials in Hepatocellular carcinoma in USA (PO) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top